{"name":"WindMIL Therapeutics","slug":"windmil-therapeutics","ticker":"","exchange":"","domain":"","description":"WindMIL Therapeutics is a biotechnology company focused on developing innovative cell therapies for cancer. The company's lead program, MILs™ - NSCLC, was in development for non-small cell lung cancer but has been discontinued. WindMIL continues to explore new opportunities in the field of immuno-oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWdGRTVzOWhMVlJyUkU3eXc2SjFDbl9lbm93VmphbEtwRXBybklIbjB1Njhvdk5KaXdDNkRURXdWaTlySWxaaUFuZVFjZlZPYVR4cWRNRkpzeUlKRjJsYVlUX0pIdWpsTkJRWlJLNm85ZHFZZG9ndHlSRy1xQXFNb3RWX0lpME9SOEJ1VFNCVzREWTA?oc=5","date":"2025-12-17","type":"pipeline","source":"Insightace Analytic","summary":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOLTZUMnVZWlNkS2dkWnlXTFNBd3JkTGdWYmU0S0dkMFd6a3pheS02cy0tdVB3X25WT1FoS0NQMjZVSkFTZXF1QnpVZFllb1FEVkJqWUExTDRfYWFDOFp1eGJzUVNYV19RZk1QdnJIVzZMWi1nakg2X19PandDdkE4V0s0akFMcGdBT21QYzJndWZhNVBjM2drNHlXekU0Tjc3SHFEVjdWY2NYeHV6?oc=5","date":"2025-07-16","type":"pipeline","source":"BioBuzz","summary":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem - BioBuzz","headline":"21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-25","type":"deal","source":"Business Wire","summary":"Monoclonal Antibody Collaboration and Licensing Deals Trends Report 2024 with Directory of 974 Partnering Deals Signed by the World's Leading Life Science Companies Since 2016 - ResearchAndMarkets.com","headline":"Monoclonal Antibody Collaboration and Licensing Deals Trends Report 2024 with Directory of 974 Partnering Deals Signed b","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOeW5uV2ZNcEp5NGhCMFd6OXZoaEpOVlRoRFl5RXhWRTFyQ2VKQlNGWDhva2pPbnVQeVl2LS03N1lHNXl5SXBEWXJLRXEzT2VmZm5pYkYtY1pLMjlwY0VjUkYzT0RJZE9uRG01bEN5RHVhSkVlWjNlVUxBSHBMTmNYdF9RaF96QnA0N3NUcUFKZ3VuM3hBeC1hQ2JveHY4d1U3NHl4SFRCLUdpTG1wa1I2Ul82SGVmNGNSM05WNHNoTkVnMHBRNG9YZ1d5bGd4NzlobnBlMVZtUUUySGF5LU5VWnRlUUppendwSERTMzIxLWRJZEg1UzR3NEJrVGs4eEhCdTVKM012Ym1lblcwLTFNYw?oc=5","date":"2022-11-10","type":"pipeline","source":"The ASCO Post","summary":"Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC? - The ASCO Post","headline":"Sotorasib: A New Standard of Care for Second- or Third-Line Treatment of KRAS G12C–Mutated NSCLC?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNbjlYNUpQQ3pfUTdLTW5IRWw4LUJKZUJYMmRqMk11cFRYRDFEa1I1NDFweHp0X1EtNmN4STdmZk5mc3lVY29OdlkxVUtNUVZRT2tSTm9lVGFDVjBvUHJCQ0RSSTdJZFoxUklFVXdVRTdweVFITWhqSDMyc0x6a2NHZUtqTUhycW9hXy1TNU9FbmZPT01jOFNhOVQ4LU1MMkVsWG1SbjRqbDh5OFZaVnlRYkwyNi01VG1kOGc?oc=5","date":"2021-09-17","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—AltruBio snags new CMO with resume at Sublimity, Ardea, Amgen and Abbott - Fierce Biotech","headline":"Chutes & Ladders—AltruBio snags new CMO with resume at Sublimity, Ardea, Amgen and Abbott","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFdsczl6V0xsMXdIelp4MzlYNVdPMmRKSTZXRF82WDZfN3FteW8zbEoyWlhLT1laQmhTbF9iUFlQZzk1dVVOVkJzaEN2cFdxNzQ1R2UxUFUyQnljUVVHZDJiQ014MGFxNTNJWjVxT3EyUWFnSnM5angxaFdYdm56R3NGR01uT0pnblJLYlhYRDYtS1dRbWlrWGs4NmozOHN3dVJlZGlLTHgzMmIxV3dKYkl6eDM3Y3BpRFZHeWRjeDRFR0w2YlVwYVZuYVFFOWdDWGkzeUdOM0VDYzFPM2tCYWtjbkNFZVBXOU9NSA?oc=5","date":"2021-05-06","type":"pipeline","source":"GlobeNewswire","summary":"WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer - GlobeNewswire","headline":"WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ0IwbmM0dk4yWTg4MUluZG1JSWRtc09ORG9rNEVld1FyYm52UnFRLUh4ekVoYzJvRlFNSkRtN1hfd1FfV1RmbnJtREs4VHZvRmd2S2diV0NkbjhpSjJQVmJEZHV1MGI2aDBVT2tHNllKVkdzRUstVGIxamhjckdISTdma0V4QlRobThQR25PQVlucTZ5RlNqM0MtbDZDNVh2MVlrYXk3RnY0LWJjdFNqODBtWjYxZkRwVHJkejRWbw?oc=5","date":"2021-05-06","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Former Merck R&D chief Perlmutter takes reins at Eikon, applying Nobel-winning tech to drug discovery - Fierce Biotech","headline":"Chutes & Ladders—Former Merck R&D chief Perlmutter takes reins at Eikon, applying Nobel-winning tech to drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNFR5aXFCQUFFYkd3Q00zLWtnV3VvZWl4UGJWeHlXdC1oYm1GS1M0ZF9FWVVuX0FpcTg4bW9mWU5JSFpuUG9FWFZfOGJ4M1F1Z2M0RjRIVHdXdlVZMTJEbGxfN1diX1Z2WXE4aXlCcVdnaVIzVU5iWThqOU1yU3gwal9ibGlqdHpudzB4QTZ2YjNsc3lNcktPSWx0bkhzMVp3b2tEQlhjMGNCTjN4TERuQlFPNA?oc=5","date":"2020-03-16","type":"pipeline","source":"BioProcess International","summary":"Grist for the MIL: CDMO Cognate making cell therapies for WindMIL - BioProcess International","headline":"Grist for the MIL: CDMO Cognate making cell therapies for WindMIL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOUll5ajdvU21SSUd3STMzM1NBaXhpQ2tqdWw3eHdJMmxIMk82QW5Bb21XSmNwYUtlU3VpZ3N2MHNYWGFYRjFrRWFSblZXTkxWY1E1a0NROWd1Ulg3Q1pxYTJJcC1qR1BWSkZ6VmNpdEFTLXJ3RXhwbktUb1RNUDFqRWdtS200czhISDAxUzZLUV9KVmV3bGdxbGFJdkZHMEhz?oc=5","date":"2019-04-25","type":"pipeline","source":"Fierce Biotech","summary":"WindMIL Therapeutics interim CEO Hayden steps up to the plate - Fierce Biotech","headline":"WindMIL Therapeutics interim CEO Hayden steps up to the plate","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}